Eiger BioPharmaceuticals Inc (EIGR):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C7965)
◆英語タイトル:Eiger BioPharmaceuticals Inc (EIGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7965
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:66
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Eiger BioPharmaceuticals Inc (Eiger), formerly Celladon Corp is a clinical-stage biopharmaceutical company that focuses on the development and commercializationof novel drugs for the treatment of orphan diseases. The company provides pipeline products such as Lonafarnib and Lambda, which are in Phase 2 trials used for the treatment of hepatitis delta virusinfection; Exendin 9-39, a phase 2 program for post-bariatric hypoglycemia;Ubenimex, a phase 2 program for lymphedema and pulmonary arterial hypertension. It offers late-stage portfolio products candidates that potential to address diseases for which unmet medical services. Eiger provides clinical development and commercialization of broad range of therapeutics. The company offers post bariatric hypogiycemia prevention services. Eiger is headquartered in Palo Alto, California, the US.

Eiger BioPharmaceuticals Inc (EIGR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12
Venture Financing 13
Eiger BioPharma Raises USD3 Million in Venture Financing 13
Celladon Raises USD3 Million in Venture Financing 14
Eiger BioPharma Raises USD6 Million in Venture Financing 15
Eiger Biopharma Raises US$1 Million In Third Tranche Of Series A Financing 16
Partnerships 17
Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17
Merger 18
Eiger BioPharma Merges with Celladon 18
Licensing Agreements 20
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21
Eiger BioPharma Enters into Licensing Agreement with Stanford University 22
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23
Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25
Equity Offering 26
Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26
Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28
Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30
Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32
Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33
Asset Transactions 35
Eiger BioPharma Sells Mydicar to Theragene Pharma 35
Eiger BioPharmaceuticals Inc – Key Competitors 36
Eiger BioPharmaceuticals Inc – Key Employees 37
Eiger BioPharmaceuticals Inc – Locations And Subsidiaries 38
Head Office 38
Other Locations & Subsidiaries 38
Recent Developments 39
Financial Announcements 39
Aug 10, 2018: Eiger Biopharmaceuticals announces second quarter 2018 financial results 39
May 11, 2018: Eiger BioPharmaceuticals Reports First Quarter 2018 Financial Results 40
Mar 12, 2018: Eiger BioPharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results 41
Nov 09, 2017: Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results 42
Aug 14, 2017: Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results 44
May 12, 2017: Eiger BioPharmaceuticals Reports First Quarter 2017 Financial Results 45
Mar 23, 2017: Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results 47
Corporate Communications 49
Jan 08, 2018: Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors 49
Jan 03, 2018: Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer 50
Sep 18, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors 51
Jun 14, 2017: Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors 52
Apr 18, 2017: Eiger BioPharmaceuticals appoints new lead for development of PBH treatment 53
Product News 54
04/18/2017: Eiger Announces Industry Veteran Lisa Porter, M.D. to Lead Development of Exendin 9-39 for the Treatment of Post-Bariatric Hypoglycemia 54
Product Approvals 55
Sep 05, 2017: Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 55
Jul 27, 2017: Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 56
May 03, 2017: Eiger Announces U.S. IND Filing of Pegylated Interferon Lambda for Hepatitis Delta Virus Infection – LIMT HDV: Lambda Interferon MonoTherapy in HDV Study Enrolling 57
Clinical Trials 58
Aug 14, 2018: Eiger BioPharmaceuticals completes enrolment in Prevent trial 58
Mar 26, 2018: Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia 59
Oct 23, 2017: Eiger Announces Positive Phase 2 Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the American Association for the Study of Liver Diseases Meeting 60
Oct 02, 2017: Eiger Announces Presentation on Lambda at the American Association for the Study of Liver Diseases Meeting 61
Jul 24, 2017: Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 62
Jun 12, 2017: Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego 63
Jun 06, 2017: Eiger Completes Enrollment in Phase 2 Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients 65
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Eiger BioPharma Acquires Assets and Rights to exendin 9-39 from Tracey McLaughlin and Colleen Craig 12
Eiger BioPharma Raises USD3 Million in Venture Financing 13
Celladon Raises USD3 Million in Venture Financing 14
Eiger BioPharma Raises USD6 Million in Venture Financing 15
Eiger Biopharma Raises US$1 Million In Third Tranche Of Series A Financing 16
Eiger BioPharma Enters into Collaboration Agreement with Progeria Research 17
Eiger BioPharma Merges with Celladon 18
Eiger BioPharmaceuticals Enters into Licensing Agreement with Bristol-Myers Squibb 20
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Post-Bariatric Surgical Hypoglycemia 21
Eiger BioPharma Enters into Licensing Agreement with Stanford University 22
Eiger BioPharma Enters into Licensing Agreement with Stanford University for Pulmonary Arterial Hypertension 23
Eiger BioPharma Enters into Licensing Agreement with Nippon Kayaku 24
Eiger BioPharma Enters into Licensing Agreement with Janssen Pharma for Tipifarnib 25
Eiger BioPharma Prices Public Offering of Shares for USD40 Million 26
Eiger BioPharma Raises USD18.5 Million in Public Offering of Shares 28
Eiger BioPharma Raises USD20 Million in Public Offering of Shares 30
Eiger BioPharma Plans to Raise up to USD25 Million in Public Offering of Shares 32
Eiger BioPharma Raises USD39.5 Million in Private Placement of Shares 33
Eiger BioPharma Sells Mydicar to Theragene Pharma 35
Eiger BioPharmaceuticals Inc, Key Competitors 36
Eiger BioPharmaceuticals Inc, Key Employees 37
Eiger BioPharmaceuticals Inc, Subsidiaries 38

List of Figures
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Eiger BioPharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Eiger BioPharmaceuticals Inc (EIGR):製薬・医療:M&Aディール及び事業提携情報(Eiger BioPharmaceuticals Inc (EIGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆